

314, T. V. Indusstrial Estate, S.K. Ahire Marg, Worli, Mumbai - 400 030. India

> Tel.: + 91 22 6663 5456 Fax: +91 22 6663 5460

E-mail: auro@aurolabs.com Web: www.aurolabs.com

Reg. Off. / Mfg. Unit: K-56, M. I. D. C. Tarapur, Dist. Palghar, Maharashtra - 401506. CIN No. L33125MH1989PLC051910

Date: June 21, 2021

To
BSE Limited,
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

Reg: Security Code No. 530233:

Sub: Outcome of the Board Meeting dated June 21, 2021:

Dear Sir / Ma'am,

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform you that the Board of Directors at their Meeting held today (i.e. **Monday, June 21, 2021**), has transacted the following business:

➤ Approved the Audited Standalone Financial Results of the Company for the quarter & year ended on March 31, 2021 as recommended by the Audit Committee.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are enclosing herewith the following:

- ➤ Audited Standalone Financial Results for the quarter & year ended March 31, 2021 along with the Statement of Assets and Liabilities of the Company and Cash-Flow Statement as on that date.
- > Auditors Report on the Financial Results for the quarter & year ended March 31, 2021.
- ➤ Declaration regarding Auditor's Report with unmodified opinion on the Audited Standalone Financial Results of the Company for the financial year ended on March 31, 2021.

The Meeting of the Board commenced at 2.45 p.m. and concluded at 3.30 p.m.



The results will be published in the newspaper pursuant to Regulation 47(1) (b) of SEBI (LODR) Regulations, 2015 in due course.

Kindly take the same on record and acknowledge.

Thanking You,

Yours Faithfully,

For AURO LABORATORIES LIMITED

SIDDHARTHA DEORAH WHOLE TIME DIRECTOR

DIN: 00230796

Encl.: as above

AURO LABORATORIES LIMITED CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR BOISAR, DIST. PALGHAR 401506 , MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com

ANNEXURE - I

5.5	ANNEXURI			/D	ا ما ما ما	
PAR		COD THE OUT	TED AND VES	 	In Lakhs exc	cept EPS)
	STATEMENT OF AUDITED FINANCIAL RESULTS	S FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2021				ndod
		24.02.2024	Quarter Ended		Year Ended	
Sr.	Park a Land	31.03.2021	31.12.2020	31.03.2020	31.03.2021	31.03.2020
No.	Particulars	(Ref. Note 4)	(Unaudited)	(Ref. Note 4)	(Audited)	(Audited)
1	Uncome from Operations			· · · · · · · · · · · · · · · · · · ·		
	Income from Operations	1 256 46	1,310.90	942.83	5,425.18	4,379.06
2	(a) Net Sales/Income from Operations (Net) Other Income	1,356.46 17.17	25.05	38.19	75.78	97.26
	Other meome	17.17	20.00	30.19	15.16	51.20
3	Total Revenue (1 + 2)	1,373.63	1,335.95	981.02	5,500.96	4,476.32
	Total Revenue (1 + 2)	1,575.05	1,000.00	301.02	3,300.30	4,470.52
4	Expenses					
	a. Consumption of raw material	518.36	609.89	367.69	2,743.09	2,342.21
	b. Purchase of Stock-in-trade	0.60		30.86	21.03	56.61
	c. (Increase) / decrease in Finished Goods stock	76.05	13.50	119.97	90.71	49.18
	in trade and work in progress		<u>'</u>			
	d. Employee benefits expense	178.58	157.34	184.91	603.62	527.54
	e. Finance Cost	25.03	4.88	21.00	45.83	57.79
	f. Depreciation and amortisation expenses	27.56	26.00	23.33	103.56	102.33
	g. Other Expenses	278.18	243.96	156.52	842.58	776.48
	Total Expenses (4)	1,104.36	1,055.57	904.29	4,450.42	3,912.14
5	Profit / (Loss) before exceptional and extraordinary items and					
	tax (3 ± 4)	269.27	280.38	76.73	1,050.54	564.18
6	Exceptional items	200.27	202.20	- 70.70	4 050 54	504.40
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)	269.27	280.38	76.73	1,050.54	564.18
8	Extraordinary items	000.07	200 20	70.70	4 050 54	504.40
9	Profit / (Loss) before tax (7 ± 8)	269.27	280.38	76.73	1,050.54	564.18
10	Tax expense	404.04	77.40		220.00	450.40
	(a) Current tax expenses for current year	104.91	77.10	24.12	320.09	152.48
	(b) MAT credit (where applicable)	42.40			42.40	6.25
44	(c) Deferred tax	12.49	202.20	6.25	717.96	6.25 405.45
11	Profit / (Loss) for the period from continuing operation (9± 10)	151.87	203.28	46.36	717.30	400.45
	Profit / (Loss) for discontinuing operations			-		
13	Tax expense of discontinuing operations Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)	151.87	203.28	46.36	717.96	405.45
15	Other Comprehensive Income	1.76	7.89	11.22	1.76	11.22
16	Total Comprehensive Income for the period (14 ± 15)	153.63	211.17	57.58	719.72	416.67
17	Paid-up equity share capital	623.25	623.25	623.25	623.25	623.25
17	(Face value of Rs. 10 each)	023.25	023.23	023.25	023.25	023.23
17	Reserves excluding Revaluation Reserves as				2,235.01	1,526.51
17	per balance sheet of previous accounting year)	 			2,200.01	1,020.01
18	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):					
	(a) Basic	2.44	3.26	0.74	11.52	6.51
	(b) Diluted	2.44	3.26	0.74	11.52	6.51



Notes on financial results:-

- The above audited financial results for the quarter and year ended 31st March, 2021 were reviewed by the Audit Committee and thereafter approved by the Board of Directors at meeting held on 21st June, 2021.
- The Company operates in single segment i.e. "Pharmaceuticals", and hence does not have any additional disclosures to be made under Ind As 108 on operating Segments.
- 3) The above audited results, published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, have been prepared in accordance with Indian Accounting Standards (IND AS) notified under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015; Companies (Indian Accounting Standards) (Amendment) Rules, 2016 and guidelines issued by the Securities and Exchange Board of India (SEBI) and other accounting principles generally accepted in India.
- 4) Figures of the Quarter ended on 31st March, 2021 & 31st March, 2020 are the balancing figures between audited figures in respect of the full financial year and the published year to the date upto the third quarter of the respective financial year.
- 5) Figures for the Previous period have been regrouped/reclassified wherever necessary to conform to current period's classifications.

FOR & BEHALF OF BOARD OF DIRECTORS

AURO LABORATORIES LIMITED

SIDDHARTHA DEORAH WHOLE TIME DIRECTOR DIN NO. 00230796

Place : Mumbai Date : 21.06.2021

Auro Laboratories Limite	d			
Statement of Assets and Liabilities (Ind AS)				
Particulars	As at 31.03.2021	(Rs. In Lakh As at 31.03.2020		
	Audited	Audited		
A ASSETS				
1. Non-Current Assets		ĺ		
(a) Property, Plant and Equipment	4 255 67	4 400 50		
(b) Capital Work -in-Progress	1,355.67	1,423.52		
(c) Investment Property	13.40	11.60		
(d) Financial Assets	-	-		
(i) Investments	4.00			
(ii) Loans	4.88	4.88		
	-	-		
(iii) Others	-	-		
(e) Other non-current assets - Capital Advance	-	-		
2. Current assets				
(c) Inventories	254.67	406.25		
(b) Financial Assets	201.07	-		
(i) Investments	_	_		
(ii) Trade Reveivables	729.90	577.98		
(iii) Cash and cash equivalents	1,082.14	503.46		
(iv) Bank balances other than (iii) above	371.49	64.96		
(v) Loans	371.49	04.90		
(vi) Others	377.13	242.17		
(c) Other Current Assets	377.13	, 242.17		
TOTAL ASSETS	4189.28	3234.82		
B EQUITY AND LIABILITIES				
1. Equity	· ·			
(a) Equity Share Capital	622.25	000.05		
(b) Other Equity	623.25	623.25		
(b) Other Equity	2,235.01	1,526.51		
2. Liabilities				
(I) Non-Current Liabilities				
(a) Financial Liabilities	203.88	180.98		
(i) Other Financial Liabilities	112.00	134.62		
(b) Provisions	112.00	134.02		
(c) Deferred Tax Liabilities (Net)	168.40	155.91		
(-) 20101100 (00)	100.40	100.91		
(II) Current Liabilities	<u> </u>	-		
(a) Financial Liabilities	_	*		
(i) Trade Payables	574.96	473.83		
(b) Other Current Liabilities	166.88	130.64		
(c) Provisions	104.90	9.08		
	104.90	3 .00		
	4490.20	2224 02		
(d) Current Tax Liabilities (net) TOTAL EQUITY AND LIABILITIES	4189.28	3234		



Cash Flow Statement

Particulars		For the year ended 31.03.2021		For the year ended 31.03.2020	
	Amount	Amount	Amount	Amount	
A. Cash flow from operating activities					
Net Profit / (Loss) before extraordinary items and tax		1,050.54		564.18	
Add: Adjustments for:		The state of the s			
Depreciation and amortisation	103.56		102.33		
Other Non Cash Items	1.76	***	11.23		
Finance costs	45.84	151.16	57.79	171.35	
		1,201.70		735.53	
Less. Adjustment for:					
Interest income	18.01		7.01		
Dividend income	0.03	18.04	0.06	7.07	
Operating profit / (loss) before working capital changes		1,183.66		728.46	
Changes in working capital:					
Adjustments for (increase) / decrease in operating assets:					
Inventories	151.59		(68.87)		
Trade receivables	(151.91)		272.40	**	
Loans and advances	(138.07)		26.44		
Other Bank Balance	3.10	*	4.31		
Other non-current assets		(135.29)		234.28	
		1,048.37		962.74	
Adjustments for increase / (decrease) in operating liabilities:	****				
Trade payables	101.13		(44.49)		
Other current liabilities	36.24		(8.63)		
Other long-term liabilities	V		()		
Short-term provisions	95.82		20.43		
Long-term provisions					
		233.19		(32.69)	
Cash flow from extraordinary items		1,281.56		930.05	
Cash generated from operations		1,281.56		930.05	
Net income tax (paid) / refunds		1,201.00		930.03	
Net cash flow from / (used in) operating activities (A)		1,281.56		930.05	



B. Cash flow from investing activities				
Capital expenditure on fixed assets, including capital advance	(37.51)		(67.23)	
Proceeds from sale of fixed assets			····	
Interest received				
- Others	18.01		7.01	
Dividend received				
- Others	0.03		0.06	a and the second to the second
		(19.47)		(60.16)
Net income tax (paid) / refunds		(331.32)		(160.60)
Net cash flow from / (used in) investing activities (B)		(350.79)		(220.76)
C. Cash flow from financing activities				
Proceeds from long-term borrowings				
Repayment of borrowings & Net increase / (decrease) in				
working capital borrowings	(43.12)		(80.76)	
Proceeds from other short-term borrowings	66.02		(353.19)	
Repayment of other short-term borrowings	(22.62)		(59.88)	
Finance cost	(45.84)		(57.79)	
		(45.56)		(551.62)
Cash flow from extraordinary items		-		-
Net cash flow from / (used in) financing activities (C)		(45.56)		(551.62)
Net increase/(decrease) in Cash & cash equivalents (A+B+C)		885.22		157.66
Cash and cash equivalents at the beginning of the year		568.41		410.75
Cash and cash equivalents at the end of the year		1,453.63		568.41

FOR & BEHALF OF BOARD OF DIRECTORS

SIDDHARTHA DEORAH WHOLE TIME DIRECTOR DIN NO. 00230796

Place :-Mumbai Date: 21.06.2021



To,
The Board of Directors,
Auro Laboratories Limited.

- 1. We have audited the accompanying Statement of Standalone Financial Results of Auro Laboratories Ltd. ("the company") for the quarter and year ended March 31, 2021, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016.
- 2. This Statement is the responsibility of the Company's Management and is approved by the Board of Directors. The Statement as it relates to the quarter ended March 31, 2021, has been compiled from the related interim condensed standalone financial statements prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") and as it relates to the year ended March 31, 2021, had been compiled from the related annual standalone financial statements prepared under Section 133 of the Companies Act, 2013 read with rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such interim condensed standalone financial statements and annual standalone financial statements.

Further, we report that the figures for the quarter ended March 31, 2021 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2021 and the published year to date figures up to December 31, 2020 being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated above as required under the Listing Regulations and circular.

3. We conducted our audit in accordance with the Standards on Auditing issued by Institute of Chartered Accountants of India. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the statement is free from material misstatement(s).



An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the statement. The procedures selected depend on auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal financial control. An audit also includes evaluating the appropriateness of the accounting policies used and reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the statements.

We believe that the evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.

- 4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) is presented in accordance with requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as modified by Circular No. "CIR/CFD/FAC/62/2016" dated July 05, 2016 and "CIR/IMD/DF1/69/2016" dated August 10, 2016, and
 - (ii) gives a true and fair view, in conformity with aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, of the profit, total comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2021.

For Khurdia Jain & Co.

Chartered Accountants

(Firm Reg. No. 120263)

Sampat Khurdia

Partner


Membership No. 033615

Place: Mumbai Date: 21/06/2021

UDIN: 21033615AAAADB6667

120263 W

PERED ACC



314, T. V. Indusstrial Estate, S.K. Ahire Marg, Worli, Mumbai - 400 030. India

Tel.: + 91 22 6663 5456

Fax: +91 22 6663 5460 E-mail: auro@aurolabs.com Web: www.aurolabs.com

Reg. Off. / Mfg. Unit: K-56, M. I. D. C. Tarapur, Dist. Palghar, Maharashtra - 401506. CIN No. L33125MH1989PLC051910

Date: June 21, 2021

To
The Deputy General Manager,
BSE Limited,
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dala1 Street,
Mumbai - 400 001.

Reg: Security Code No. 530233

Sub: <u>Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015.</u>

Pursuant to the provision of Regulation 33 (3) (d) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended by SEBI Notification No. SEBI / LAD-NRO / GN / 2016-17 / 001 dated May 25, 2016 read with SEBI Circular No. CIR / CFD / CMD / 56 / 2016 dated May 27, 2016, We hereby declared that the Statutory Auditors of the Company M/s. Khurdia Jain & Co, Chartered Accountants, Mumbai (Firm Registration No. 120263W) have issued the Audit Reports with Unmodified Opinion in respect of the Audited Standalone Financial results for the quarter & year ended on March 31, 2021.

Kindly take the same on your record.

Thanking you,

For AURO LABORATORIES LIMITED

SIDDHARTHA DEORAH WHOLE TIME DIRECTOR

My Wy No W

DIN: 00230796